-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sodium diquasophosphate is a P2Y2 subject exciter, which acts on the epithelial epithelial and cup cell membrane p2Y2 on the conjunctivity, by increasing the concentration of calcium ions in the cell, promote the secretion of water and mucous protein, and thus improve the symptoms of dry eye disease.
the drug was developed with the authorization of Inspire Pharmaceuticals (Merck subsidiary) and was first approved in Japan in October 2010 for the treatment of dry eye disease under the product name Diquas®, with a specification of 3% (5 mL).
was approved for import in October 2017, with the product named Lieth.
public data show that the drug will have sales of about $35 million in public health facilities in 2019.
the Insight database, Hengrui's tetquasol sodium was listed in July and is currently in line for review.
from: Insight Database ()